Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agios Pharmaceuticals, Inc. (AGIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. As a Delaware corporation with common stock traded on the Nasdaq Global Select Market, Agios submits current and periodic reports to the U.S. Securities and Exchange Commission that document its financial condition, governance decisions, and material events.
For investors analyzing AGIO, key filings include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s rare disease business, risk factors, research and development spending, and details on commercial-stage activities around products such as PYRUKYND (mitapivat) and AQVESME (mitapivat). Form 8-K current reports capture material developments, including quarterly financial results, stock incentive plan amendments, director elections, regulatory updates, and safety-related communications.
This page also surfaces proxy statements and exhibits referenced in filings, which can provide insight into stock incentive plans, non-employee director compensation, and shareholder voting outcomes. Where applicable, Form 4 and other ownership filings can be used to review insider transactions by directors and officers.
Stock Titan enhances these SEC documents with AI-powered summaries that explain complex sections in plain language, helping users quickly understand what each filing means for Agios’ rare disease strategy, PK activation franchise, and capital allocation. Real-time updates from EDGAR ensure that new AGIO filings appear promptly, while structured access to 10-Ks, 10-Qs, 8-Ks, and ownership reports allows for efficient due diligence on this commercial-stage biopharmaceutical company.
Agios Pharmaceuticals Chief Legal Officer James William Burns exercised 8,500 performance share units into 8,500 shares of common stock. The PSUs vested when a specified regulatory milestone was determined to be met on April 2, 2026. On the same date, 3,280 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these transactions, Burns directly holds 49,306 shares of Agios common stock.
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Sarah Gheuens exercised performance share units that converted into 8,500 shares of common stock on April 2, 2026 after a specified regulatory milestone was achieved.
Each performance share unit represented a contingent right to receive one share of common stock, and the grant was originally made on March 1, 2024. Following this vesting and exercise, Gheuens sold 2,940 shares of common stock at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, she directly owns 80,277 common shares, which include 311 shares purchased through the company’s employee stock purchase plan.
Agios Pharmaceuticals' Chief Financial Officer Cecilia Jones exercised performance share units and sold shares primarily to cover taxes. She converted 8,500 performance share units into 8,500 shares of common stock after a specified regulatory milestone was determined to have been met on April 2, 2026. On the same date, 3,141 shares were sold at $34.71 per share to satisfy tax withholding obligations under durable automatic sale instructions included in her March 1, 2024 performance share unit agreement, which is structured to be consistent with the Rule 10b5-1(c) affirmative defense. After these transactions, she directly held 54,998 shares of common stock, including 311 shares acquired through the company’s employee stock purchase plan.
Agios Pharmaceuticals Chief Commercial Officer Tsveta Milanova reported a vesting and tax-related sale of shares. On April 2, 2026, 8,500 performance share units were exercised into 8,500 shares of common stock at $0.00 per share, reflecting the vesting of performance-based equity compensation tied to a specified regulatory milestone.
On the same date, 3,262 shares of common stock were sold at $34.71 per share to cover tax withholding obligations, executed under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, Milanova directly owned 46,829 shares of Agios common stock.
Agios Pharmaceuticals executive Krishnan Viswanadhan reported an exercise-and-sell transaction tied to performance share units (PSUs). On April 2, 2026, 8,100 PSUs converted into 8,100 shares of common stock at $0.00 per share when a specified regulatory milestone was achieved.
On the same date, 2,959 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, he held 10,282 shares of Agios common stock directly.
Agios Pharmaceuticals Chief Executive Officer Brian Goff reported vesting and settlement of performance share units tied to regulatory milestones, resulting in the delivery of 39,028 shares of common stock. On the same date, 19,068 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these compensation-related transactions, he holds 184,508 common shares directly.
AGIO reported Form 144 sale/transfer activity tied to executive restricted stock units. The filing lists 19,068 shares associated with vesting of RSUs on 04/02/2026 and discloses a prior sale of 18,055 shares on 03/02/2026 for $522,873.
AGIO submitted a Form 144 notice to sell 3,141 shares of Common Stock tied to the vesting of Restricted Stock Units on 04/02/2026. The excerpt also shows a prior sale by Cecilia Jones of 5,035 shares on 03/02/2026.
AGIO Therapeutics reported a notice under Rule 144 for common stock related to an insider transaction. The filing shows 2,959 shares tied to the vesting of Restricted Stock Units on 04/02/2026. The filing also records that Krishnan Viswanadhan had 2,959 shares listed under "Securities Sold During The Past 3 Months" with an associated dollar figure of $82,260.00 dated 03/05/2026.
AGIO affiliate filed a Form 144 notice for proposed sales of Common Stock tied to the vesting of restricted stock units on 04/02/2026. The filing lists quantities and dollar values for recent sales by Tsveta Milanova, including 2,868 shares ($83,057.00) on 03/02/2026 and 2,872 shares ($77,601.00) on 01/05/2026.